MCID: LYM027
MIFTS: 56

Lymphopenia malady

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Lymphopenia

Aliases & Descriptions for Lymphopenia:

Name: Lymphopenia 12 29 52 42 14 69
Lymphocytopenia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:614
ICD10 33 D72.810
ICD9CM 35 288.51
MeSH 42 D008231
SNOMED-CT 64 48813009
UMLS 69 C0024312

Summaries for Lymphopenia

Disease Ontology : 12 A leukopenia that is the condition of having an abnormally low level of lymphocytes in the blood.

MalaCards based summary : Lymphopenia, also known as lymphocytopenia, is related to hepatitis and rheumatoid arthritis. An important gene associated with Lymphopenia is RAG1 (Recombination Activating 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Immunoglobulins and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and breast, and related phenotypes are endocrine/exocrine gland and hematopoietic system

Wikipedia : 71 Lymphocytopenia, or lymphopenia, is the condition of having an abnormally low level of lymphocytes in... more...

Related Diseases for Lymphopenia

Diseases related to Lymphopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 256)
id Related Disease Score Top Affiliating Genes
1 hepatitis 29.0 CTLA4 IFNG IL10 IL2
2 rheumatoid arthritis 28.9 CTLA4 FOXP3 IFNG IL10 IL2 IL2RA
3 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 12.1
4 immunodeficiency 13 11.3
5 idiopathic cd4-positive t-lymphocytopenia 11.3
6 immunodeficiency 14 10.8
7 sideroblastic anemia with b-cell immunodeficiency, periodic fevers, and developmental delay 10.8
8 short stature, microcephaly, and endocrine dysfunction 10.8
9 immunodeficiency 17, cd3 gamma deficient 10.8
10 immunodeficiency, x-linked, with magnesium defect, epstein-barr virus infection and neoplasia 10.8
11 immunodeficiency 22 10.7
12 reticular dysgenesis 10.7
13 immunodeficiency 37 10.7
14 immunodeficiency 40 10.7
15 severe combined immunodeficiency, b cell-negative 10.7
16 immunodeficiency 8 10.7
17 neutropenia, severe congenital 4, autosomal recessive 10.7
18 schimke immunoosseous dysplasia 10.7
19 immunodeficiency 49 10.7
20 immunodeficiency 50 10.7
21 non-amyloid monoclonal immunoglobulin deposition disease 10.2 FAS IL2RA PTPN22
22 t-cell prolymphocytic leukemia 10.2 FAS IL2RA PTPN22
23 polyomavirus allograft nephropathy 10.2 FAS IL2RA PTPN22
24 hemangioma of intra-abdominal structure 10.2 FASLG IFNG
25 anterior corneal pigmentation 10.1 FAS IL2RA PTPN22
26 mental retardation, x-linked, snyder-robinson type 10.1 CD55 CD59
27 dieulafoy lesion 10.1 IFNG SELL UNC119
28 paroxysmal nocturnal hemoglobinuria 10.1 FOXP3 IFNG IL7
29 chromophobe adenoma 10.1 IL2 SELL
30 mixed cell type cancer 10.1 FAS FASLG IFNG
31 pseudo-meigs syndrome 10.1 FAS FASLG IL10
32 systemic lupus erythematosus 10.1
33 lupus erythematosus 10.1
34 celiac disease 3 10.1 CTLA4 INS
35 immunoglobulin g deficiency 10.1 FASLG IL10 IL2RA
36 subungual glomus tumor 10.1 FOXP3 IFNG
37 neutral lipid storage disease with myopathy 10.1 CTLA4 INS PTPN22
38 tungiasis 10.1 IFNG IL10 RAG1
39 lymphoma 10.0
40 asymptomatic neurosyphilis 10.0 IFNG IL10 IL2RA
41 ciliary discoordination, due to random ciliary orientation 10.0 IFNG IL10 IL2RA
42 alcoholic liver cirrhosis 10.0 FAS FOXP3 IL2 IL2RA
43 neutropenia 10.0
44 paratyphoid fever 10.0 FOXP3 IFNG IL10
45 hyperaldosteronism, familial, type ii 10.0 FASLG IL2 IL2RA SELL
46 parametritis 10.0 IFNG IL2 IL2RA
47 kcnq3-related disorders 10.0 FOXP3 IFNG IL2
48 autosomal recessive congenital methemoglobinemia 10.0 FAS IFNG IL2
49 neonatal jaundice 10.0 FOXP3 IFNG IL10
50 benign eccrine breast spiradenoma 10.0 FASLG IFNG IL10

Graphical network of the top 20 diseases related to Lymphopenia:



Diseases related to Lymphopenia

Symptoms & Phenotypes for Lymphopenia

MGI Mouse Phenotypes related to Lymphopenia:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.48 IL7 IL7R INS PTPN22 RAG1 SELL
2 hematopoietic system MP:0005397 10.48 CD55 CD59 CTLA4 FAS FASLG FOXP3
3 immune system MP:0005387 10.4 G6PC3 IFNG IL10 IL2 IL2RA IL2RG
4 homeostasis/metabolism MP:0005376 10.39 CD59 CTLA4 FAS FASLG FOXP3 G6PC3
5 cellular MP:0005384 10.38 IL2 IL2RG IL7R INS PTPN22 RAG1
6 cardiovascular system MP:0005385 10.35 CTLA4 FAS FASLG FOXP3 IFNG IL10
7 digestive/alimentary MP:0005381 10.34 CTLA4 FAS FASLG FOXP3 IFNG IL10
8 growth/size/body region MP:0005378 10.28 FAS FOXP3 G6PC3 IFNG IL10 IL2
9 mortality/aging MP:0010768 10.28 PTPN22 CD59 CTLA4 FAS FASLG FOXP3
10 liver/biliary system MP:0005370 10.2 IL2 INS PTPN22 RAG1 SELL CTLA4
11 integument MP:0010771 10.13 CTLA4 FAS FASLG FOXP3 IFNG IL10
12 neoplasm MP:0002006 10.06 FAS FASLG IFNG IL10 IL2 IL2RG
13 normal MP:0002873 10.02 CTLA4 FAS FASLG FOXP3 IFNG IL10
14 no phenotypic analysis MP:0003012 9.91 FOXP3 IFNG IL10 IL2 IL2RG IL7
15 renal/urinary system MP:0005367 9.86 CD59 FAS FASLG FOXP3 IFNG INS
16 reproductive system MP:0005389 9.81 CD59 FAS FASLG FOXP3 IFNG IL10
17 respiratory system MP:0005388 9.73 CTLA4 FAS FASLG FOXP3 IFNG IL10
18 vision/eye MP:0005391 9.32 FAS FASLG FOXP3 IFNG IL10 IL2

Drugs & Therapeutics for Lymphopenia

Drugs for Lymphopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
2 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
3 gamma-Globulins Phase 4,Phase 3
4 Immunoglobulins, Intravenous Phase 4,Phase 3
5 Rho(D) Immune Globulin Phase 4,Phase 3
6
Zinc Approved Phase 3 7440-66-6 32051 23994
7
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
8
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
9
Selenium Approved, Vet_approved Phase 3 7782-49-2
10 Gastrointestinal Agents Phase 3,Phase 1
11 Peripheral Nervous System Agents Phase 3,Phase 1
12 Immunoglobulin G Phase 3,Phase 1
13 Protective Agents Phase 3
14 Antiemetics Phase 3,Phase 1
15 Neurotransmitter Agents Phase 3
16 Trace Elements Phase 3
17 Dopamine Agents Phase 3
18 Dopamine Antagonists Phase 3
19 Dopamine D2 Receptor Antagonists Phase 3
20 Micronutrients Phase 3
21 Autonomic Agents Phase 3
22 Antioxidants Phase 3
23 glutamine Nutraceutical Phase 3
24 Whey Protein Nutraceutical Phase 3
25
Melphalan Approved Phase 2,Phase 1 148-82-3 4053 460612
26
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
27
Busulfan Approved, Investigational Phase 1, Phase 2 55-98-1 2478
28
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
29
Thiotepa Approved Phase 2,Phase 1 52-24-4 5453
30
Lenalidomide Approved Phase 2 191732-72-6 216326
31
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
32
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
33
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
34
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
35
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
36
Vidarabine Approved Phase 2,Phase 1 24356-66-9 32326 21704
37
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
38
Dacarbazine Approved, Investigational Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
39
alemtuzumab Approved, Investigational Phase 2 216503-57-0
40
Temozolomide Approved, Investigational Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
41
Lenograstim Approved Phase 2,Phase 1 135968-09-1
42
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
43
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
44
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
45
Mechlorethamine Approved Phase 2 51-75-2 4033
46
Pembrolizumab Approved Phase 2 1374853-91-4
47
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
48
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
49
Gemcitabine Approved Phase 2 95058-81-4 60750
50
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903

Interventional clinical trials:

(show top 50) (show all 96)
id Name Status NCT ID Phase
1 A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Completed NCT01289847 Phase 4
2 Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis Completed NCT01321164 Phase 3
3 Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. Completed NCT00278954 Phase 3
4 Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients Completed NCT00220766 Phase 3
5 The CRISIS Prevention Study Terminated NCT00395161 Phase 3
6 GVAX in Advanced Prostate Cancer Patients Made Lymphopenic Unknown status NCT00122005 Phase 1, Phase 2
7 Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients Completed NCT01368107 Phase 2
8 Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy Completed NCT00815321 Phase 2
9 Cetuximab and Lenalidomide in Head and Neck Completed NCT01133665 Phase 2
10 Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis Completed NCT02780167 Phase 2
11 Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS) Completed NCT00885833 Phase 1, Phase 2
12 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
13 EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer Recruiting NCT02001272 Phase 2
14 Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Recruiting NCT02179086 Phase 2
15 A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients Recruiting NCT03019809 Phase 2
16 Gene Therapy for WAS Follow-up Recruiting NCT02333760 Phase 1, Phase 2
17 Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases Recruiting NCT01852370 Phase 1, Phase 2
18 Immune Disorder HSCT Protocol Recruiting NCT01821781 Phase 2
19 Gene Therapy for WAS Recruiting NCT01347346 Phase 1, Phase 2
20 Gene Therapy for Wiskott-Aldrich Syndrome (WAS) Recruiting NCT01347242 Phase 1, Phase 2
21 A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation Active, not recruiting NCT00405327 Phase 2
22 A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients Active, not recruiting NCT02640807 Phase 2
23 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2
24 Gene Therapy for Wiskott-Aldrich Syndrome Active, not recruiting NCT01515462 Phase 2
25 Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome Active, not recruiting NCT01410825 Phase 1, Phase 2
26 Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients Active, not recruiting NCT00909363 Phase 2
27 Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide Not yet recruiting NCT03139851 Phase 2
28 Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE) Terminated NCT00839436 Phase 1, Phase 2
29 Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer Terminated NCT00771810 Phase 2
30 A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients Terminated NCT00849875 Phase 2
31 Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer Terminated NCT01220128 Phase 2
32 Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells Terminated NCT02512679 Phase 2
33 Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer Completed NCT00693095 Phase 1
34 Safety Study of IL-7 in HIV-infected Patients (Inspire) Completed NCT00477321 Phase 1
35 Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma Completed NCT00091143 Phase 1
36 A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects Completed NCT02211469 Phase 1
37 A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. Completed NCT01466322 Phase 1
38 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
39 Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant Completed NCT00684008 Phase 1
40 Study of Dasatinib (BMS-354825) in Patients With Solid Tumors Completed NCT00339144 Phase 1
41 Interleukin-2 Treatment for Wiskott-Aldrich Syndrome Completed NCT00774358 Phase 1
42 Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome Completed NCT00160355 Phase 1
43 Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives Recruiting NCT00001529 Phase 1
44 EGFRvIII CAR T Cells for Newly-Diagnosed GBM Recruiting NCT02664363 Phase 1
45 Prostate Stem Cell Antigen (PSCA)-Specific CAR T Cells In Subjects With Non-Resectable Pancreatic Cancer Recruiting NCT02744287 Phase 1
46 Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms Recruiting NCT02743611 Phase 1
47 Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL Recruiting NCT00881920 Phase 1
48 Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers Recruiting NCT03144934 Phase 1
49 Clinical Trial of GX-I7 in Healthy Volunteers Recruiting NCT02860715 Phase 1
50 Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) Recruiting NCT02287311 Phase 1

Search NIH Clinical Center for Lymphopenia

Cochrane evidence based reviews: lymphopenia

Genetic Tests for Lymphopenia

Genetic tests related to Lymphopenia:

id Genetic test Affiliating Genes
1 Lymphopenia 29

Anatomical Context for Lymphopenia

MalaCards organs/tissues related to Lymphopenia:

39
T Cells, B Cells, Breast, Thymus, Bone, Bone Marrow, Liver

Publications for Lymphopenia

Articles related to Lymphopenia:

(show top 50) (show all 569)
id Title Authors Year
1
Profound T-cell lymphopenia associated with prenatal exposure to purine antagonists detected by TREC newborn screening. ( 28065337 )
2017
2
Dysplasia of Granulocytes in a Patient with HPV Disease, Recurrent Infections, and B Lymphopenia: A Novel Variant of WHIM Syndrome? ( 28512628 )
2017
3
Large Deletion of MAGT1 Gene in a Patient with Classic Kaposi Sarcoma, CD4 Lymphopenia, and EBV Infection. ( 27770395 )
2017
4
Apoptosis-induced lymphopenia in sepsis and other severe injuries. ( 27812767 )
2016
5
FTY720-Induced Lymphopenia does not Aggravate Mortality in a Murine Model of Polymicrobial Abdominal Sepsis. ( 27559700 )
2016
6
A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. ( 27532020 )
2016
7
Lymphopenia can be a useful biomarker of adverse events related to vemurafenib. ( 26810349 )
2016
8
Lymphopenia and autoimmunity: A double-edged sword. ( 27343993 )
2016
9
TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model. ( 26959227 )
2016
10
CD4 T Cell Help via B Cells Is Required for Lymphopenia-Induced CD8 T Cell Proliferation. ( 26912319 )
2016
11
Lymphopenia as a predictor of sarcoidosis in patients with uveitis. ( 26729767 )
2016
12
Patterns of Radiation-Associated Lymphopenia in Children with Cancer. ( 26745229 )
2016
13
Lymphopenia in treatment-naive relapsing multiple sclerosis. ( 27559542 )
2016
14
IL-15 signaling promotes adoptive effector T-cell survival and memory formation in irradiation-induced lymphopenia. ( 27158441 )
2016
15
JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7. ( 27421731 )
2016
16
Component of Caramel Food Coloring, THI, Causes Lymphopenia Indirectly via a Key Metabolic Intermediate. ( 27185637 )
2016
17
Worsening of Lymphopenia during Apremilast Treatment. ( 27920684 )
2016
18
PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter? ( 27343070 )
2016
19
Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer. ( 27354621 )
2016
20
Lymphocytosis and Lymphopenia Induced by Imported Infectious Diseases: A Controlled Cross-Sectional Study of 17,229 Diseased German Travelers Returning from the Tropics and Subtropics. ( 27068397 )
2016
21
A Clinical Approach to a Child with Hypoalbuminemia and Lymphopenia. ( 27026169 )
2016
22
Risk Factors and Clinical Significance of Lymphopenia in Survivors of the Fontan Procedure for Single-Ventricle Congenital Cardiac Disease. ( 26897303 )
2016
23
Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens. ( 27051233 )
2016
24
Immune Control Despite Protracted Lymphopenia After Chemoradiation in an Elite Controller. ( 26949716 )
2016
25
Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. ( 26725885 )
2016
26
The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. ( 27214202 )
2016
27
Cutaneous Extranodal NK/T Cell Lymphoma Mimicking Cellulitis in a HIV Positive Patient without Lymphopenia. ( 28035700 )
2016
28
Distinct roles of T-cell lymphopenia and the microbial flora for gastrointestinal and CNS autoimmunity. ( 26740263 )
2016
29
Profound lymphopenia is associated with a lower risk of hepatic cytolysis during antithymocyte globulin administration. ( 26799506 )
2016
30
Lymphopenia, Infectious Complications, and Outcome in Spontaneous Intracerebral Hemorrhage. ( 28004330 )
2016
31
Lymphopenia at 4 Days Postoperatively Is the Most Significant Laboratory Marker for Early Detection of Surgical Site Infection Following Posterior Lumbar Instrumentation Surgery. ( 27994779 )
2016
32
Lymphopenia and Elevated Blood C-Reactive Protein Levels at Four Days Postoperatively Are Useful Markers for Early Detection of Surgical Site Infection Following Posterior Lumbar Instrumentation Surgery. ( 27114760 )
2016
33
Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy. ( 26814381 )
2016
34
CD4 T Helper Cells Instruct Lymphopenia-Induced Memory-Like CD8 T Cells for Control of Acute LCMV Infection. ( 28066432 )
2016
35
Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma. ( 25760636 )
2015
36
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. ( 26550483 )
2015
37
Impact of early lymphopenia on the risk of febrile neutropenia and hematological toxicity. ( 26578043 )
2015
38
Does lymphopenia or macrocytosis reflect 6-thioguanine levels in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine? ( 26425841 )
2015
39
Combined immunodeficiency with CD4 lymphopenia and sclerosing cholangitis caused by a novel loss-of-function mutation affecting IL21R. ( 25769540 )
2015
40
Conditional Deletion of TAK1 in T Cells Reveals a Pivotal Role of TCRI+I^+ Intraepithelial Lymphocytes in Preventing Lymphopenia-Associated Colitis. ( 26132627 )
2015
41
The Presence of Hypothermia Within 24 Hours of Sepsis Diagnosis Predicts Persistent Lymphopenia. ( 25793436 )
2015
42
DUSP4-mediated accelerated T-cell senescence in idiopathic CD4 lymphopenia. ( 25733583 )
2015
43
Selective Treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease. ( 26301814 )
2015
44
Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time. ( 25604093 )
2015
45
Systematic neonatal screening for severe combined immunodeficiency and severe T-cell lymphopenia: Analysis of cost-effectiveness based on French real field data. ( 25840725 )
2015
46
Lymphopenia in Patients with Single-ventricle Heart Disease after the Fontan Operation. ( 26554755 )
2015
47
Severe Lymphopenia is Associated with Elevated Plasma Interleukin-15 Levels and Increased Mortality during Severe Sepsis. ( 25692255 )
2015
48
p53 mediates loss of hematopoietic stem cell function and lymphopenia in Mysm1 deficiency. ( 25710881 )
2015
49
Persistent lymphopenia is an independent predictor of mortality in critically ill emergency general surgical patients. ( 26501197 )
2015
50
Levels of feline infectious peritonitis virus in blood, effusions, and various tissues and the role of lymphopenia in disease outcome following experimental infection. ( 25532961 )
2015

Variations for Lymphopenia

Expression for Lymphopenia

Search GEO for disease gene expression data for Lymphopenia.

Pathways for Lymphopenia

Pathways related to Lymphopenia according to GeneCards Suite gene sharing:

(show all 41)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CD55 CD59 CTLA4 FASLG IFNG IL10
2
Show member pathways
13.67 FAS FASLG IFNG IL10 IL2 IL2RA
3
Show member pathways
13.52 IFNG IL10 IL2 IL2RA IL2RG IL7
4
Show member pathways
13.42 FAS FASLG IL10 IL2 IL2RA IL2RG
5
Show member pathways
13.39 FASLG IFNG IL10 IL2 IL2RA IL2RG
6
Show member pathways
13.33 FAS FASLG IL10 IL2 IL2RA IL2RG
7
Show member pathways
12.83 FAS FASLG IFNG IL2 IL2RA IL2RG
8
Show member pathways
12.82 IL2 IL2RA IL2RG IL7 IL7R INS
9
Show member pathways
12.76 CD55 CTLA4 FAS FASLG FOXP3 IFNG
10
Show member pathways
12.63 FOXP3 IFNG IL10 IL2 IL2RA IL2RG
11 12.59 FASLG G6PC3 IL2 IL2RA IL2RG IL7
12
Show member pathways
12.46 CTLA4 FAS IFNG IL10 IL2
13
Show member pathways
12.36 CTLA4 IL2 IL2RA IL2RG
14
Show member pathways
12.21 IFNG IL10 IL2 IL2RA IL2RG IL7
15 12.15 CTLA4 FAS FASLG FOXP3 IFNG IL10
16
Show member pathways
12.09 IFNG IL2 IL2RA IL2RG
17
Show member pathways
12.09 FASLG G6PC3 IL10 IL7R INS RAG1
18
Show member pathways
12.04 FASLG IFNG IL2 IL2RA IL2RG
19 11.95 CD55 CD59 IL2RA IL7 IL7R
20 11.83 CD59 IFNG IL10 IL2 IL2RA IL7
21 11.8 IFNG IL10 IL2 IL7R SELL
22 11.78 CTLA4 FOXP3 IL10 IL2RA
23 11.78 IFNG IL10 IL2 IL2RA IL7 IL7R
24 11.75 IFNG IL10 IL2 IL2RA
25
Show member pathways
11.73 FASLG FOXP3 IL2 IL2RA IL2RG
26
Show member pathways
11.73 CTLA4 FASLG FOXP3 IFNG IL2 IL2RA
27
Show member pathways
11.68 FASLG IFNG IL2 IL2RA IL2RG
28 11.61 FAS FASLG IFNG IL2
29
Show member pathways
11.54 IL2RA IL2RG IL7 IL7R
30 11.49 CD59 IL2RA INS
31 11.43 FAS FASLG IFNG IL10
32 11.41 IL2RG IL7R RAG1
33 11.41 FOXP3 IFNG IL10 IL2 IL2RA IL2RG
34 11.4 IFNG IL2 IL2RA IL2RG
35 11.34 IFNG IL10 IL2 IL7
36 11.3 IL2RG IL7 IL7R RAG1
37 11.27 IFNG IL2 IL2RA
38 11.23 IFNG IL10 IL2
39 11.21 FASLG IL10 IL2 IL7
40
Show member pathways
11.18 IL2 IL2RA IL2RG
41
Show member pathways
10.83 FAS FASLG FOXP3 IFNG IL10 IL2

GO Terms for Lymphopenia

Cellular components related to Lymphopenia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 CD55 CD59 FAS FASLG IFNG IL10
2 transport vesicle GO:0030133 9.5 CD55 CD59 INS
3 endoplasmic reticulum-Golgi intermediate compartment membrane GO:0033116 9.43 CD55 CD59 INS
4 cell surface GO:0009986 9.43 CD55 CD59 FAS FASLG IL2RA SELL
5 external side of plasma membrane GO:0009897 9.23 CTLA4 FAS FASLG IFNG IL2RA IL2RG

Biological processes related to Lymphopenia according to GeneCards Suite gene sharing:

(show all 34)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 FOXP3 IFNG IL7R INS PTPN22
2 cell surface receptor signaling pathway GO:0007166 9.96 CD59 IFNG IL2RA IL7R
3 MAPK cascade GO:0000165 9.95 IL2 IL2RA IL2RG INS
4 cell-cell signaling GO:0007267 9.92 FASLG IL10 IL2 IL7 INS
5 adaptive immune response GO:0002250 9.91 CTLA4 IFNG IL2 RAG1
6 response to lipopolysaccharide GO:0032496 9.9 FAS FASLG IL10 PTPN22
7 negative regulation of inflammatory response GO:0050728 9.76 FOXP3 IL10 IL2 IL2RA
8 extrinsic apoptotic signaling pathway GO:0097191 9.74 FAS FASLG IFNG
9 positive regulation of T cell proliferation GO:0042102 9.73 CD59 IFNG IL2 IL2RA
10 negative regulation of tumor necrosis factor production GO:0032720 9.71 FOXP3 IL10 PTPN22
11 T cell differentiation GO:0030217 9.69 IL2 IL7R PTPN22
12 negative regulation of T cell proliferation GO:0042130 9.67 CTLA4 FOXP3 IL10 IL2RA
13 negative regulation of growth of symbiont in host GO:0044130 9.66 IFNG IL10
14 negative regulation of B cell proliferation GO:0030889 9.66 CTLA4 IL10
15 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.65 FAS FASLG
16 negative regulation of interleukin-17 production GO:0032700 9.63 FOXP3 IFNG
17 positive regulation of regulatory T cell differentiation GO:0045591 9.63 FOXP3 IL2
18 positive regulation of isotype switching to IgG isotypes GO:0048304 9.62 IFNG IL2
19 positive regulation of MHC class II biosynthetic process GO:0045348 9.61 IFNG IL10
20 necroptotic signaling pathway GO:0097527 9.59 FAS FASLG
21 activation-induced cell death of T cells GO:0006924 9.58 FAS IL2RA
22 negative regulation of immune response GO:0050777 9.58 CTLA4 FOXP3 IL2RA
23 negative regulation of T-helper 17 cell differentiation GO:2000320 9.56 FOXP3 IL2
24 T cell homeostasis GO:0043029 9.56 FAS FOXP3 IL2RA RAG1
25 interleukin-2-mediated signaling pathway GO:0038110 9.55 IL2RA IL2RG
26 negative regulation of lymphocyte proliferation GO:0050672 9.5 FOXP3 IL2 IL2RA
27 regulation of T cell homeostatic proliferation GO:0046013 9.49 IL2 IL2RA
28 interleukin-7-mediated signaling pathway GO:0038111 9.48 IL2RG IL7R
29 immune response GO:0006955 9.36 CTLA4 FAS FASLG IFNG IL10 IL2
30 inflammatory cell apoptotic process GO:0006925 9.33 FAS FASLG IFNG
31 positive regulation of T cell differentiation GO:0045582 9.26 IL2 IL2RA IL7 RAG1
32 negative regulation of apoptotic process GO:0043066 10.04 CD59 FAS IL10 IL2 IL7
33 positive regulation of cell proliferation GO:0008284 10.04 FASLG IFNG IL2 IL7 INS
34 immune system process GO:0002376 10.02 CD55 CTLA4 IL2 IL2RA PTPN22

Molecular functions related to Lymphopenia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 glycosphingolipid binding GO:0043208 9.32 IL2 SELL
2 interleukin-2 receptor activity GO:0004911 9.26 IL2RA IL2RG
3 interleukin-2 binding GO:0019976 9.16 IL2RA IL2RG
4 cytokine activity GO:0005125 9.02 FASLG IFNG IL10 IL2 IL7
5 interleukin-7 receptor activity GO:0004917 8.96 IL2RG IL7R

Sources for Lymphopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....